Gain detailed insights into the trading activity of Congress members for Labcorp Holdings on our government trades page. Stay updated on how elected officials are investing in LH.

Labcorp Holdings - Government Trades

Laboratory Corp

Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.

Labcorp Holdings

pharma lab worker ai

Analyst Color

Earnings

Large Cap

News

Guidance

Health Care

Movers

Trading Ideas

General

Laboratory Corporation Of America Holdings

NVTA

Labcorp beats Q1 sales estimates, driven by organic growth and acquisitions. Revised 2024 guidance projects higher EPS and sales growth. The acquisition of Invitae is expected to bolster Labcorp&#39;s specialty testing capabilities.

Labcorp&#39;s Q1 Revenue Surpasses Forecasts; Analysts Scrutinize Invitae Deal

Business,Partnership,Meeting,Concept.,Image,Businessmans,Handshake.,Successful,Businessmen,Handshaking

Equities

Labcorp acquires certain operations of Opko Health subsidiary BioReference Health. The assets Labcorp is acquiring generate about $100 million in annual revenue, with the transaction valued at $237.5 million.

Labcorp Expands Diagnostic Reach With Strategic Deal For Select Assets Of BioReference Health

dementia-Photo by Gerd Altmann via Pixabay

BIIB

ESALY

A less invasive alternative to PET scans, these tests offer quick identification for emerging treatments. Learn more about the latest advancements in Alzheimer&#39;s detection.

Evolving Landscape For Alzheimer&#39;s Blood Tests Gains Momentum Amid Inaccuracy Concerns

Short Ideas

Insider Trades

Pre-Market Outlook

Markets

MRVL

The Nasdaq 100 closed higher by over 1% on Monday. Investors, meanwhile, focused on some notable insider trades.

SLB, Marvell Technology And 2 Other Stocks Insiders Are Selling

Media

FTRE

Activist hedge fund Starboard Value holds a 

Why Fortrea Holdings Shares Are Gaining Today

RHHBF

RHHBY

RHHVF

Blood tests for diagnosing Alzheimer&#39;s disease are eagerly awaited, but it may be a couple of years before they become a routine diagnostic tool.

While several blood tests for Alzheimer&#39;s diagnosis are in development, none are approved by regulators or insurance reimbursement. 

Is There A Blood Test for Alzheimer&#39;s? Progress Underway, But Not Quite Ready

Government

BRKR

TSX:CEMI

CODX

EXAS

TSX:FLDM

HOLX

LMDX

OSUR

QDEL

QGEN

TWST

In response to the escalating spread of the virus nationwide, the Biden administration declared that it would recommence offering free at-home COVID tests to American households starting next Monday.

Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year

Regulations

The FDA is preparing to increase regulation of a widely used class of tests conducted by laboratories to detect cancer, measure cholesterol, and identify other health issues.

The FDA is developing a proposal to ensure these tests&#39; effectiveness and accuracy. 

FDA Readies Proposal for Increased Oversight on Lab-developed Tests

Small Cap

Analyst Ratings

MYGN

Diagnostic and cancer test products provider Exact Sciences Corp. (NASDAQ: EXAS) saw its shares spike over 17% on its Q1 2023 earnings results. The company is known for its flagship colon cancer detection test Cologuard.

Exact Sciences Serves Investors Exactly What They Wished For

Labcorp&#39;s Q1 Revenue Falls On Decline In COVID-19 Testing Sales

Labcorp Holdings Inc

LERER HIPPEAU ACQUISITION CORP

Linkhome Holdings Inc

Leo Holdings Corp II Ordinary Shares - Class A

Leo Holdings Corp II

LAZARD HEALTHCARE ACQUISITION CORP. I

Leo Holdings Corp II Warrants (07/01/2028)

Lucira Health Inc Ordinary Shares

LIC HSG FIN S/GDR 144A by Lic Housing Finance Ltd.

LIGHTHOUSE GLOGAL HLDGS by Lighthouse Global Holdings Inc.

Lighthouse Global Holdings Inc

LEHMAN BRO HLDC/T 6.00% M by Lehman Brothers Holdings, Inc.

Lehman Brothers Holdings Capital Trust V

LEADER HILL CORP by Leader Hill Corp.

LIONHEART IV CORP

LIFEHOUSE RETIREMENT PPTY by LifeHouse Retirement Properties, Inc.

LIONHEART III CORP

LIGHTSTONE VALUE REIT by Lightstone Value Plus REIT Inc.

Lightstone Value Plus REIT I Inc

LIANHUA SUPERMKT HLDGS CO by Lianhua Supermarket Holdings Ltd.

Lianhua Supermarket Holdings Co Ltd

LIANHUA SPRMKT UNSP/ADR by Lianhua Supermarket Holdings Ltd.

L3Harris Technologies Inc

Lhyfe SA

Labcorp Launches Global Trial Connect For Increasing Speed Of Clinical Trials

Across the recent three months, 4 analysts have shared their insights on Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Labcorp Holdings, presenting an average target of $238.75, a high estimate of $255.00, and a low estimate of $213.00. This current average represents a 6.37% decrease from the previous average price target of $255.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1717099227_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of Labcorp Holdings by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$243.00</td>
<td>$261.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$255.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Stephanie Davis</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$213.00</td>
<td>$234.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$244.00</td>
<td>$255.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Labcorp Holdings. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Labcorp Holdings compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Labcorp Holdings's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Labcorp Holdings's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Labcorp Holdings analyst ratings.</a>
<h2>Discovering Labcorp Holdings: A Closer Look</h2>
Labcorp Holdings Inc is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Financial Milestones: Labcorp Holdings's Journey</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Labcorp Holdings's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 4.57%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 7.18%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Labcorp Holdings's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.88% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Labcorp Holdings's ROA stands out, surpassing industry averages. With an impressive ROA of 1.37%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.75.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 4 Analyst Projections For Labcorp Holdings

JP Morgan analyst Lisa Gill maintains Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Overweight and lowers the price target from $261 to $243.

Price Target

JP Morgan Maintains Overweight on Labcorp Holdings, Lowers Price Target to $243

Acquisition advances Labcorp's specialty testing strategy in key areas&nbsp;such as oncology and rare diseases
Key milestone reached in Invitae's Chapter 11 process
BURLINGTON, N.C. and SAN FRANCISCO, May 7, 2024 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4160920-1&amp;h=1415596713&amp;u=https%3A%2F%2Fwww.labcorp.com%2F&amp;a=Labcorp">Labcorp</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>), a global leader of innovative and comprehensive laboratory services, and Invitae (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NVTAQ#OTC">NVTAQ</a>), a leading medical genetics company,&nbsp; announced today that the United States Bankruptcy Court has approved the previously announced bid by Labcorp to acquire assets of Invitae.
"As a leading medical genetics company, Invitae has advanced genomics-based testing solutions across its network," said Mark Schroeder, Executive Vice President and President of Diagnostics Laboratories and Chief Operations Officer of Labcorp. "Invitae will complement our business and advance our leadership in genetic screening, diagnostics and specialty testing. This supports our goal to provide best-in-class resources and health insights for patients and physicians."
"The Court's approval of our proposed sale to Labcorp is a positive step forward in our restructuring process," said Ken Knight, President and Chief Executive Officer of Invitae. "Looking ahead, I am confident that with this transaction, Labcorp will help ensure our industry-leading genetics platform is available to all who can benefit from it."&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The transaction is expected to bolster Labcorp's genetic specialty testing capabilities, especially in key health areas such as oncology and rare diseases, aimed at enhancing patient care and providing insights into their health with improved accessibility to genetic data. The transaction also strengthens Labcorp's ability to utilize genetic data to enhance and support clinical trials and treatment regimens.
Pursuant to the asset purchase agreement, Labcorp will acquire select assets of Invitae on a going concern basis for $239 million in cash consideration, plus other non-cash consideration. Invitae and Labcorp anticipate the sale will be completed in the third quarter of 2024, subject to customary closing conditions and applicable regulatory approvals.

NVTAQ

Invitae Receives Court Approval For Sale To Labcorp; Key Milestone Reached In Invitae's Chapter 11 Process

Revealing a significant insider sell on May 1, Peter J Wilkinson, SVP at Laboratory Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>), as per the latest SEC filing.
What Happened: Wilkinson's decision to sell 2,439 shares of Laboratory Corp was revealed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000920148/000112760224013789//Archives/edgar/data/920148/000112760224013789/0001127602-24-013789-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday. The total value of the sale is $498,358.
In the Thursday's morning session, Laboratory Corp's shares are currently trading at $199.78, experiencing a down of 0.76%.
<h3>Get to Know Laboratory Corp Better</h3>
Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Financial Milestones: Laboratory Corp's Journey</h3>
Positive Revenue Trend: Examining Laboratory Corp's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 4.57% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Interpreting Earnings Metrics:
<ul>
<li>
Gross Margin: With a low gross margin of 28.25%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 2.71, Laboratory Corp showcases strong earnings per share.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.75, Laboratory Corp adopts a prudent financial strategy, indicating a balanced approach to debt management.
Valuation Overview:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 43.02 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 1.42 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Indicated by a lower-than-industry-average EV/EBITDA ratio of 16.56, the company suggests a potential undervaluation, which might be advantageous for value-focused investors.
</li>
</ul>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Important</h3>
Considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>A Closer Look at Important Transaction Codes</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000920148">Check Out The Full List Of Laboratory Corp's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Unloading: Peter J Wilkinson Sells $498K Worth Of Laboratory Corp Shares

WIIM

Labcorp shares are trading higher after the company announced that the FDA approved its nABCyte Anti-AAVRh74var HB-FE Assay, a companion diagnostic, to determine patient eligibility for treatment with BEQVEZ.

FDA Approves Labcorp's nAbCyte Anti-AAVRh74var HB-FE, Companion Diagnostic To Determine Patient Eligibility For Treatment With Beqvez (Fidanacogene Elaparvovec-dzkt), Pfizer's Recently FDA-Approved Hemophilia B Gene Therapy

In the latest quarter, 5 analysts provided ratings for Laboratory Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>), showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $242.4, a high estimate of $260.00, and a low estimate of $213.00. Experiencing a 4.19% decline, the current average is now lower than the previous average price target of $253.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1714158054_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Laboratory Corp among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan MacDonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$255.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Stephanie Davis</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$213.00</td>
<td>$234.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$244.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Michael Cherny</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$260.00</td>
<td>-</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Announces</td>
<td>In-Line</td>
<td>$240.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Laboratory Corp. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Laboratory Corp compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Laboratory Corp's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Laboratory Corp's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Laboratory Corp analyst ratings.</a>
<h2>Get to Know Laboratory Corp Better</h2>
Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Key Indicators: Laboratory Corp's Financial Health</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Laboratory Corp's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 3.54%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -5.51%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Laboratory Corp's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -2.12% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Laboratory Corp's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.99%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Laboratory Corp's debt-to-equity ratio is below the industry average. With a ratio of 0.76, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings For Laboratory Corp

Truist Securities analyst Ryan MacDonald maintains Laboratory Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Buy and lowers the price target from $270 to $255.

Truist Securities Maintains Buy on Laboratory Corp, Lowers Price Target to $255

Barclays analyst Stephanie Davis maintains Laboratory Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Equal-Weight and lowers the price target from $234 to $213.

Barclays Maintains Equal-Weight on Laboratory Corp, Lowers Price Target to $213

Baird analyst Eric Coldwell maintains Laboratory Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Outperform and lowers the price target from $255 to $244.

Baird Maintains Outperform on Laboratory Corp, Lowers Price Target to $244

Thursday,&nbsp;Labcorp&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) reported first-quarter sales increased 4.6% to $3.18 billion, beating the consensus of $3.12 billion. Base Business grew 6.7%.
The increase was due to organic revenue of 2.3%, acquisitions, net of divestitures of 1.8%, and foreign&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/n38426008/labcorp-announces-2024-first-quarter-results" rel="noreferrer noopener">currency translation of 0.5%</a>.&nbsp;
The 2.3% increase in organic revenue was driven by a 4.2% increase in the company&#8217;s organic Base Business, partially offset by a (1.9%) decrease in COVID-19 PCR testing (COVID-19 Testing).&nbsp;
The adjusted operating income margin for the quarter was 14.3%, almost unchanged from 14.7% a year ago.
Diagnostics Laboratories revenue for the quarter was&nbsp;$2.48&nbsp;billion, an increase of 4.1%.
Total volume increased by 3.4% as acquisition volume, net of divestitures contributed 2.2%, while organic volume increased by 1.2%.&nbsp;
Organic volume was up due to a 2.6% increase in the Base Business, including the negative impact&nbsp;from adverse weather&nbsp;of approximately 1%.&nbsp;Price/mix was up 1.9%.
Biopharma Laboratory Services revenue reached $710.9 million, up 7.5% due to organic growth of 5.1% and foreign currency translation of 2.4%.
Guidance:&nbsp;Labcorp expects 2024 adjusted EPS of $14.45-$15.35&nbsp;versus prior&nbsp;guidance&nbsp;of&nbsp;$14.30-$15.40&nbsp;and consensus of&nbsp;$14.82.
Labcorp&#8217;s&nbsp;2024 sales are expected to increase by 4.8%-6.4% compared to prior guidance of 4.7%-6.5%, Y/Y.
The guidance includes Diagnostics Laboratories sales growth guidance of 4.8%-6.0% and Biopharma Laboratory Services sales growth of 3.7%-5.7%, compared to prior guidance of 3.2%-4.8% and 5.5%-7.5%, respectively.
On&nbsp;Wednesday, the company said it will acquire bankrupt genetic test maker&nbsp;Invitae&nbsp;Corporation&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/NVTA#OTC">NVTA</a>) for $239 million, a few months after the genetic test maker&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/02/36938401/softbank-backed-genetic-testing-invitaes-descent-from-7b-valuation-to-near-bankruptcy" rel="noreferrer noopener">filed for bankruptcy.</a>
Labcorp expects this transaction would generate approximately $275 million-$300 million in annual revenue, with&nbsp;the majority in specialty testing areas such as&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/n38420784/labcorp-announces-winning-bid-for-select-assets-of-invitae" rel="noreferrer noopener">oncology and rare diseases</a>.
William Blair&nbsp;suggests investors may seek clarification regarding the deal due to Invitae&#8217;s increased cash burn. If Invitae can control this, the acquisition could enhance its portfolio by utilizing Labcorp&#8217;s infrastructure, especially in oncology and rare diseases testing.&nbsp;
Labcorp&#8217;s aggressive M&amp;A approach, with over&nbsp;$475 million&nbsp;spent recently, may not significantly boost segment growth but could create long-term benefits by expanding solutions and customer reach in a changing market.
Price Action: LH shares are down 4.7% at $197.86 at last check Thursday.
Now Read: <a href="https://www.benzinga.com/markets/equities/24/04/38436183/magnificent-7-tumble-wipe-out-300-billion-on-metas-weak-guidance-q1-stagflation-woes">Magnificent 7 Tumble, Wipe Out $300 Billion On Meta&#8217;s Weak Guidance, Q1 Stagflation Woes</a>
Image generated using artificial intelligence via Midjourney.

Labcorp's Q1 Revenue Surpasses Forecasts; Analysts Scrutinize Invitae Deal

Laboratory Corp shares are trading lower. The company reported Q1 financial results.

Labcorp Expects 2024 Adjusted EPS Of $14.45-$15.35 Versus Prior Guidance Of $14.30-$15.40 And Consensus Of $14.82

Laboratory Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) reported quarterly earnings of $3.68 per share which beat the analyst consensus estimate of $3.48 by 5.75 percent. This is a 6.36 percent increase over earnings of $3.46 per share from the same period last year. The company reported quarterly sales of $3.177 billion which beat the analyst consensus estimate of $3.117 billion by 1.93 percent. This is a 4.58 percent increase over sales of $3.038 billion the same period last year.

Earnings Beats

Laboratory Corp Q1 2024 Adj EPS $3.68 Beats $3.48 Estimate, Sales $3.177B Beat $3.117B Estimate

<ul>
<li>Advances Labcorp strategy to launch and scale specialty testing&nbsp;in areas such as oncology and rare diseases</li>
<li>Transaction requires court approval, with confirmation expected on&nbsp;May 6, 2024</li>
</ul>

Reported Earlier, Labcorp Wins Bid For Invitae Assets To Boost Specialty Testing In Oncology And Rare Diseases

Labcorp Announced The Availability Of The Nation's First Test For Glial Fibrillary Acidic Protein, A Critical Blood-based Biomarker For Early Detection Of Neurodegenerative Diseases And Neurological Injuries

The FDA Granted Emergency Use Authorization To Labcorp's Mpox PCR Test Home Collection Kit To Diagnose Infection With Non-Variola Orthopoxvirus, As The First Mpox At-home Collection Kit Authorized By FDA

Labcorp is&nbsp;expanding its portfolio of solutions that support the development of novel therapies for oncology with the launch of its proprietary platform for molecular residual disease (MRD),&nbsp;Labcorp&nbsp;Plasma Detect, enhancement of its circulating tumor DNA (ctDNA) genomic profiling solution Labcorp&nbsp;Plasma Complete, and continued investment in expanding its capabilities in cell and gene therapy.

Labcorp Reports Strategic Expansion Of Its Precision Oncology Portfolio

The launch of the Labcorp Plasma Detect MRD solution further enhances Labcorp&#39;s leadership in precision oncology across the solid tumor oncology care continuum. Labcorp Plasma Detect builds on the successful deployment of two existing liquid biopsy platforms &ndash; Labcorp&reg; Plasma Focus&trade;, a targeted approach, and Labcorp&reg; Plasma Complete&trade;, a comprehensive profiling solution, both with utility for clinical research and clinical applications. All three solutions were developed by Personal Genome Diagnostics, Inc. (PGDx&reg;), a Labcorp company, and are performed in the PGDx Baltimore CAP-accredited and CLIA-certified laboratory.

Labcorp Launches Labcorp Plasma Detect Extending Leadership Into Molecular Residual Disease (MRD) Clinical Research

Diamond Hill Large Cap Strategy Q1 2024 Market Commentary

Diamond Hill Large Cap Concentrated Fund Q1 2024 Market Commentary

The latest announcement is out from Laboratory (LH). Laboratory Corporation of America Holdings, a pioneer in laboratory services, will be presenti...

Laboratory Corp to Present at Annual Growth Stock Conference

Mizuho starts Fortrea at neutral, cites low near-term earnings visibility

Sell ideas in Staples and Health Care - Oppenheimer

Laboratory (LH) has provided an update. Labcorp Holding Inc.'s executive team is set to engage in the 44th Annual William Blair Growth Stock Confer...

Laboratory Holdings Executives Present at Growth Stock Conference

Top shorted S&P 500 industrial stocks at May end

Most shorted S&P 500 industrial stocks at May end

Laboratory Corporation: Limited Upside Visibility, Reiterate Hold

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on EyePoint Pharmaceuticals (EYPT – Research Report), P...

Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT), Praxis Precision Medicines (PRAX) and Laboratory (LH)

AAPL

CRBG

EYPT

HSIC

MDLZ

MSFT

NVDA

PRAX

SBAC

SMCI

TSLA

UBER

Press Releases

Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B

Intelligent Bio Solutions Screening Technologies Poised to Disrupt The Healthcare Sector: INBS, LH, ABT, DGX

FDA Approves ColoSense™ – Geneoscopy's Noninvasive Multi-target Stool RNA (mt-sRNA) Colorectal Cancer Screening Test

Invitae Receives Court Approval for Sale to Labcorp

Labcorp to Webcast Its Annual Meeting of Shareholders

Labcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk during Pregnancy

Labcorp to Speak at the 44th Annual William Blair Growth Stock Conference

Labcorp to Present Multiple Abstracts across Precision Oncology at the 2024 ASCO Annual Meeting

Labcorp Announces New Strategic Service Offerings within Precision Oncology Portfolio

Labcorp Launches Global Trial Connect to Accelerate Clinical Trials

INBS

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

AMN Healthcare Services

Astrana Health

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna Group

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Government Trades

Labcorp Holdings Inc

top performing LH trades